Clinical Trials

    Showing 1 - 4 of 4 Myasthenia Gravis

    A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis (ADAPT oculus)

    Status: Open Not Enrolling

    Investigator: Ericka Greene

    Study Coordinator: Aramide Balogun

    Phone: 713.441.6955

    The purpose of this study is to evaluate the efficacy and safety of efgartigimod PH20 SC given by a pre-filled syringe in adult patients with ocular myasthenia gravis. The study consists of a part A (approximately 7 weeks) and a part B (up to 2 years... Read more >

    A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis (RELIEVE)

    Status: Enrolling

    Investigator: Ericka Greene

    Study Coordinator: Aramide Balogun

    Phone: 713.441.6955

    This study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate the efficacy, safety and tolerability of remibrutinib in gMG patients who are on stable SOC treatment. Approximately 180 eligible participants wil... Read more >

    Long-Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies

    Status: Enrolling

    Investigator: Ericka Greene

    Study Coordinator: Aramide Balogun

    Phone: 713.441.6955

    Complement component 5 (C5) inhibition therapies have been available for patients with generalized Myasthenia Gravis (gMG) in the United States since the introduction of Soliris® in late 2017. Alexion is developing potential new therapies that leve... Read more >

    RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

    Status: Enrolling

    Investigator: Sheetal Shroff

    Study Coordinator: Delrose Vernon

    Phone: 346.238.9068

    Myasthenia gravis (MG) is a rare autoimmune disorder characterized by autoantibody responses that cause defective transmission of signals at the neuromuscular junction, resulting in a distinctive pattern of weakness. Patients with generalized MG (gMG... Read more >